Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 11/2019

01-11-2019 | Multiple Sclerosis | Correction

Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry

Authors: Michael Guger, Christian Enzinger, Fritz Leutmezer, Jörg Kraus, Stefan Kalcher, Erich Kvas, Thomas Berger, on behalf of the Austrian MS Treatment Registry (AMSTR)

Published in: Journal of Neurology | Issue 11/2019

Login to get access

Excerpt

The original version of this article unfortunately contained a mistake. First and last names of the authors were interchanged. The correct author names are given below. …
Metadata
Title
Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry
Authors
Michael Guger
Christian Enzinger
Fritz Leutmezer
Jörg Kraus
Stefan Kalcher
Erich Kvas
Thomas Berger
on behalf of the Austrian MS Treatment Registry (AMSTR)
Publication date
01-11-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 11/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-019-09535-2

Other articles of this Issue 11/2019

Journal of Neurology 11/2019 Go to the issue

Original Communication

Zona incerta deep-brain stimulation in orthostatic tremor: efficacy and mechanism of improvement

Original Communication

Motor and non-motor symptoms in blepharospasm: clinical and pathophysiological implications

Original Communication

Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry

Review

Amyloid-β and Parkinson’s disease

Original Communication

Thalassemia and Moyamoya syndrome: unfurling an intriguing association

Original Communication

The clinical and radiological profile of primary lateral sclerosis: a population-based study